Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $1.0 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Account Payables rose 15070.42% to $1.0 million in Q2 2025 from the same period last year, while for May 2025 it was -$1.7 million, marking a year-over-year increase of 7498.5%. This contributed to the annual value of -$1.7 million for FY2025, which is 7498.5% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Change in Account Payables amounted to $1.0 million in Q2 2025, which was up 15070.42% from -$3.5 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Change in Account Payables' 5-year high stood at $13.7 million during Q4 2021, with a 5-year trough of -$12.4 million in Q2 2021.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Change in Account Payables had a median value of -$367500.0 in 2023 and averaged $28555.6.
  • Its Change in Account Payables has fluctuated over the past 5 years, first skyrocketed by 21233.6% in 2023, then plummeted by 470847.46% in 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Change in Account Payables (Quarter) stood at $13.7 million in 2021, then decreased by 18.67% to $11.1 million in 2022, then crashed by 100.53% to -$59000.0 in 2023, then crashed by 4708.47% to -$2.8 million in 2024, then surged by 136.8% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q2 2025, -$3.5 million for Q1 2025, and -$2.8 million during Q4 2024.